Michael J. Tomsicek
2018 - CRISPR Therapeutics AG
In 2018, Michael J. Tomsicek earned a total compensation of $2.3M as Chief Financial Officer at CRISPR Therapeutics AG, a 4% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $209,760 |
|---|---|
| Option Awards | $1,653,972 |
| Salary | $380,000 |
| Other | $9,625 |
| Total | $2,253,357 |
Tomsicek received $1.7M in option awards, accounting for 73% of the total pay in 2018.
Tomsicek also received $209.8K in non-equity incentive plan, $380K in salary and $9.6K in other compensation.
Rankings
In 2018, Michael J. Tomsicek's compensation ranked 5,120th out of 14,244 executives tracked by ExecPay. In other words, Tomsicek earned more than 64.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,120 out of 14,244 | 64th |
Division Manufacturing | 1,931 out of 5,765 | 67th |
Major group Chemicals And Allied Products | 707 out of 2,128 | 67th |
Industry group Drugs | 591 out of 1,817 | 68th |
Industry Biological Products, Except Diagnostic Substances | 119 out of 339 | 65th |
Source: SEC filing on April 30, 2019.
Tomsicek's colleagues
We found four more compensation records of executives who worked with Michael J. Tomsicek at CRISPR Therapeutics AG in 2018.
News
CRISPR Therapeutics AG CEO Samarth Kulkarni's 2021 pay jumps 87% to $17M
April 25, 2022
CRISPR Therapeutics AG CEO Samarth Kulkarni's 2020 pay falls 44% to $9.1M
April 28, 2021
CRISPR Therapeutics AG CEO Samarth Kulkarni's 2019 pay jumps 67% to $16M
April 24, 2020
CRISPR Therapeutics AG CEO Samarth Kulkarni's 2018 pay jumps 40% to $9.7M
April 30, 2019
ABIOMED CEO Michael Minogue's 2018 pay slips 16% to $10M
June 22, 2018